The differentiation of oligodendrocyte progenitor cells (OPCs) into oligodendrocytes (OLs) promotes the remyelination in human brain. In multiple sclerosis (MS), dysfunctional OPC differentiation ...

The therapeutic landscape for multiple sclerosis (MS) is evolving beyond modulating the peripheral immune response. New strategies are now focussed on reducing inflammation and promoting the ...

BUFFALO, N.Y. — Two papers by University at Buffalo researchers reveal important new findings as to how regeneration of myelin in multiple sclerosis fails and, potentially, more efficient ways to ...

BUFFALO, N.Y. — Remyelination, the spontaneous regeneration of the fatty insulator in the brain that keeps neurons communicating, has long been seen as crucial to the next big advance in treating ...

WEST PALM BEACH, FL ― Among patients with relapsing multiple sclerosis (MS) and visual impairment who received a potential remyelinating treatment or placebo for as long as 36 weeks, median ...

EDINBURGH, Scotland--(BUSINESS WIRE)--Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological ...